BELLUS Health Inc.

lockPrivate Group

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders.

people5 Members       (0)

Corporate Profile
Group Admins:
  • Thumb 8020 monitor 200200 2
Request Membership


BELLUS Health Inc.

lockPrivateGroup

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chroni......

people5 Members       (0)

Thumb 8020 monitor 200200 2

8020 Admin

1 hour ago

8020 Admin posted a press release BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences in BELLUS HEALTH INC.

LAVAL, Quebec


BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will participate in two upcoming healthcare investor conferences.


Conference Presentation Details:


Event: SVB Leerink 9th Annual Global Healthcare Conference


Date/Time: Thursday, February 27, 2020 at 10:00 a.m. EST


Location: New York, NY


Event: Cowen and Company's 40th Annual Health Care Conference


Date/Time: Tuesday, March 3, 2020 at 8:00 a.m. EST


Location: Boston, MA


Live webcasts from the Leerink fireside chat and the Cowen conference presentation may be accessed on the Events and Presentations page under the Investors & News section of BELLUS Health's website at www.bellushealth.com. Following the events, archived webcasts and presentations will be available on the Company’s website.


About BELLUS Health (www.bellushealth.com)


BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.


Chronic cough, the lead indication for BLU-5937, is a cough lasting more than eight weeks and is associated with significant adverse physical, social and psychosocial effects on health and quality of life. It is estimated that approximately 26 million adults in the United States suffer from chronic cough with more than 2.6 million having refractory chronic cough lasting for more than a year. There is no specific therapy approved for refractory chronic cough and treatment options are limited.


Chronic pruritus, commonly known as chronic itch, is an irritating sensation that leads to scratching, and persists for longer than six weeks, which can be debilitating and has a significant impact on quality-of-life. It is a hallmark of many conditions, including atopic dermatitis (“AD”). It is estimated that chronic pruritus associated with AD affects more than 16.9 million adults in the United States.


View source version on businesswire.com: https://www.businesswire.com/news/home/20200220005180/en/



Investors:
BELLUS Health
François Desjardins
Vice-President, Finance
450-680-4525
fdesjardins@bellushealth.com


Solebury Trout
Chad Rubin
646-378-2947
crubin@troutgroup.com


Media:
Solebury Trout
Joshua R. Mansbach
646-378-2964
jmansbach@troutgroup.com



!
Thumb 8020 monitor 200200 2

8020 Admin

3 months ago

8020 Admin posted a press release BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2019 in BELLUS HEALTH INC.

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the third quarter ended September 30, 2019.


Key Updates:



  • Completion of a US$79.4 Million Offering: In September 2019, BELLUS Health completed an offering of its common shares resulting in gross proceeds to the Company of US$79.4 million;

  • Listing of Common Shares on Nasdaq: In September 2019, concurrently with the closing of the equity offering, BELLUS Health’s common shares began trading on the Nasdaq Global Market (“Nasdaq”);

  • Appointment of a Chief Medical Officer: In August 2019, BELLUS Health appointed Catherine Bonuccelli, MD to the role of Chief Medical Officer (CMO), bringing to the Company over 20 years of pharmaceutical experience with significant expertise in clinical development and commercialization of respiratory and non-respiratory products;

  • First Patient Enrolled in the Ongoing Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough: In July 2019, the Company enrolled the first patient in the Phase 2 RELIEF trial of BLU-5937 for the treatment of refractory chronic cough. The trial is evaluating the efficacy and safety of BLU-5937 and is expected to build on the Phase 1 evidence showing little to no impact on taste. The Company anticipates top-line results in mid-2020;

  • Second Indication for BLU-5937 in Chronic Pruritus to Start Phase 2 Trial in Q2 2020: In July 2019, the Company announced that it was expanding its BLU-5937 P2X3 inhibitor platform to include chronic pruritus. In September 2019, BELLUS Health presented preclinical data on BLU-5937 in pruritus at the European Society for Dermatological Research Conference. The Company expects to begin a clinical Phase 2 trial in chronic pruritus associated with atopic dermatitis, also known as eczema, in Q2 2020;

  • Key Opinion Leader (“KOL”) Meeting to Discuss the State of Chronic Cough Treatment: In July 2019, the Company held a KOL event to discuss chronic cough and its P2X3 inhibitor product candidate, BLU-5937. The event was led by Dr. Jacky Smith, Professor at the University of Manchester, United Kingdom. A replay of the event is available on the Company’s website; and

  • Cash Position: BELLUS Health concluded the third quarter with cash, cash equivalents and short-term investments totalling C$132.2 million (US$99.9 million).


“We have evolved significantly as an organization in the third quarter, solidifying our business growth strategy, and establishing our path forward from a clinical and regulatory development perspective,” said Roberto Bellini, President and Chief Executive Officer of BELLUS Health. “The past quarter was highlighted by our listing on the Nasdaq, and the completion of our US$79.4 million offering. We also bolstered our executive leadership with the appointment of industry veteran Dr. Cathy Bonuccelli to the position of Chief Medical Officer. Collectively, these achievements have positioned us for continued success, as we look toward the upcoming clinical and regulatory milestones for our product candidate, BLU-5937, in 2020.”


BLU-5937 for Chronic Cough


BELLUS Health is developing BLU-5937, a potent, highly selective, small molecule inhibitor of the P2X3 receptor, as an oral therapy to reduce cough frequency in refractory chronic cough patients.


BELLUS Health is currently conducting a Phase 2 clinical trial of BLU-5937 for patients with refractory chronic cough, which is referred to as the RELIEF (A Randomized, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Trial of BLU-5937 in Subjects with Unexplained or Refractory Chronic Cough) trial. The trial was initiated in July 2019 and the Company expects to report topline data in mid-2020.


The RELIEF trial is a randomized, double-blind, placebo-controlled, dose escalation and two-period crossover design trial to assess the efficacy, safety and tolerability of BLU-5937 at four doses: 25, 50, 100 and 200 mg BID. Doses are escalated at four-day intervals. Approximately 65 patients with refractory chronic cough are expected to be enrolled at approximately 15 clinical sites located in the United Kingdom and United States. BELLUS Health enrolled the first patient in the RELIEF trial at the end of July 2019 and is actively recruiting patients.


Phase 1 results showed that no subjects in the BLU-5937 arm receiving anticipated therapeutic doses reported any loss of taste perception, and only one subject out of 24 (<5%) reported transient and sporadic taste alteration only on the first day of dosing. No subject reported total loss of taste at any dose. The RELIEF trial will also collect taste adverse event data to potentially build on this clinical evidence.


Further details on BELLUS Health’s Phase 2 RELIEF trial for BLU-5937 can be found at https://clinicaltrials.gov/ct2/show/NCT03979638.


Currently, there is no therapy approved specifically for the treatment of refractory chronic cough, and the most advanced therapy in development has substantial tolerability issues, including significant taste alteration or loss. BLU-5937 may be a differentiated option, with little to no effect on taste.


BLU-5937 for Chronic Pruritus


In July 2019, BELLUS Health announced that it is developing BLU-5937 for a second indication, chronic pruritus. The Company believes BLU-5937 may be a viable treatment option for patients with chronic pruritus associated with atopic dermatitis (“AD”).


Preclinical studies conducted by BELLUS Health provided evidence that the ATP-induced hypersensitization mediated by P2X3 receptors in cutaneous C-fibers plays a key role in pruritus. In multiple animal models of pruritus, the Company observed that treatment with BLU-5937 resulted in significant anti-pruritic effect. The Company presented preclinical data on BLU-5937 in pruritus at the European Society for Dermatological Research Conference in September 2019.


BELLUS Health plans to initiate a randomized, double-blind, placebo-controlled, parallel group design Phase 2 clinical trial to assess the efficacy, safety, and tolerability of BLU-5937 in approximately 100 patients suffering from moderate to severe chronic pruritus associated with mild to moderate AD. The trial is expected to be a two-arm study comparing BLU-5937 to placebo, each administered orally, twice-daily (BID), for four weeks. The Company expects to initiate the trial in Q2 2020 and report topline data in mid-2021.


Read more here: https://www.quotemedia.com/portal/quote?qm_symbol=BLU&qmodStoryID=6892256027749964 

!
Thumb 8020 monitor 200200 2

8020 Admin

3 months ago

8020 Admin posted a press release BELLUS Health to Present at Jefferies Global Healthcare Conference in London in BELLUS HEALTH INC.

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company on Wednesday, November 20, 2019 at the Jefferies Global Healthcare Conference in London.


Presentation Details:


Event: Jefferies Global Healthcare Conference in London
Date/Time: Wednesday, November 20, 2019 at 9:20 a.m. GMT
Location: London


A live webcast may be accessed on the Events and Presentations page under the Investors & News section of BELLUS Health's website at www.bellushealth.com. Following the event, an archived webcast and presentation will be available on the Company’s website.


About BELLUS Health


BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.




Investors:
François Desjardins
Vice President, Finance
450-680-4525
fdesjardins@bellushealth.com

Solebury Trout
Chad Rubin
646-378-2947
crubin@troutgroup.com

Media:
Solebury Trout
Joshua R. Mansbach
646-378-2964
jmansbach@troutgroup.com


!
Thumb no photo

luc@mi3.ca

11 months ago

!

BELLUS Health Inc.

lockPrivate Group

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders.

people5 Members       (0)

Corporate Profile
Group Admins:
  • Thumb 8020 monitor 200200 2
Request Membership


BELLUS Health Inc.

lockPrivateGroup

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chroni......

people5 Members       (0)

Thumb 8020 monitor 200200 2

8020 Admin

1 hour ago

8020 Admin posted a press release BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences in BELLUS HEALTH INC.

LAVAL, Quebec


BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will participate in two upcoming healthcare investor conferences.


Conference Presentation Details:


Event: SVB Leerink 9th Annual Global Healthcare Conference


Date/Time: Thursday, February 27, 2020 at 10:00 a.m. EST


Location: New York, NY


Event: Cowen and Company's 40th Annual Health Care Conference


Date/Time: Tuesday, March 3, 2020 at 8:00 a.m. EST


Location: Boston, MA


Live webcasts from the Leerink fireside chat and the Cowen conference presentation may be accessed on the Events and Presentations page under the Investors & News section of BELLUS Health's website at www.bellushealth.com. Following the events, archived webcasts and presentations will be available on the Company’s website.


About BELLUS Health (www.bellushealth.com)


BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.


Chronic cough, the lead indication for BLU-5937, is a cough lasting more than eight weeks and is associated with significant adverse physical, social and psychosocial effects on health and quality of life. It is estimated that approximately 26 million adults in the United States suffer from chronic cough with more than 2.6 million having refractory chronic cough lasting for more than a year. There is no specific therapy approved for refractory chronic cough and treatment options are limited.


Chronic pruritus, commonly known as chronic itch, is an irritating sensation that leads to scratching, and persists for longer than six weeks, which can be debilitating and has a significant impact on quality-of-life. It is a hallmark of many conditions, including atopic dermatitis (“AD”). It is estimated that chronic pruritus associated with AD affects more than 16.9 million adults in the United States.


View source version on businesswire.com: https://www.businesswire.com/news/home/20200220005180/en/



Investors:
BELLUS Health
François Desjardins
Vice-President, Finance
450-680-4525
fdesjardins@bellushealth.com


Solebury Trout
Chad Rubin
646-378-2947
crubin@troutgroup.com


Media:
Solebury Trout
Joshua R. Mansbach
646-378-2964
jmansbach@troutgroup.com



!
Thumb 8020 monitor 200200 2

8020 Admin

3 months ago

8020 Admin posted a press release BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2019 in BELLUS HEALTH INC.

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the third quarter ended September 30, 2019.


Key Updates:



  • Completion of a US$79.4 Million Offering: In September 2019, BELLUS Health completed an offering of its common shares resulting in gross proceeds to the Company of US$79.4 million;

  • Listing of Common Shares on Nasdaq: In September 2019, concurrently with the closing of the equity offering, BELLUS Health’s common shares began trading on the Nasdaq Global Market (“Nasdaq”);

  • Appointment of a Chief Medical Officer: In August 2019, BELLUS Health appointed Catherine Bonuccelli, MD to the role of Chief Medical Officer (CMO), bringing to the Company over 20 years of pharmaceutical experience with significant expertise in clinical development and commercialization of respiratory and non-respiratory products;

  • First Patient Enrolled in the Ongoing Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough: In July 2019, the Company enrolled the first patient in the Phase 2 RELIEF trial of BLU-5937 for the treatment of refractory chronic cough. The trial is evaluating the efficacy and safety of BLU-5937 and is expected to build on the Phase 1 evidence showing little to no impact on taste. The Company anticipates top-line results in mid-2020;

  • Second Indication for BLU-5937 in Chronic Pruritus to Start Phase 2 Trial in Q2 2020: In July 2019, the Company announced that it was expanding its BLU-5937 P2X3 inhibitor platform to include chronic pruritus. In September 2019, BELLUS Health presented preclinical data on BLU-5937 in pruritus at the European Society for Dermatological Research Conference. The Company expects to begin a clinical Phase 2 trial in chronic pruritus associated with atopic dermatitis, also known as eczema, in Q2 2020;

  • Key Opinion Leader (“KOL”) Meeting to Discuss the State of Chronic Cough Treatment: In July 2019, the Company held a KOL event to discuss chronic cough and its P2X3 inhibitor product candidate, BLU-5937. The event was led by Dr. Jacky Smith, Professor at the University of Manchester, United Kingdom. A replay of the event is available on the Company’s website; and

  • Cash Position: BELLUS Health concluded the third quarter with cash, cash equivalents and short-term investments totalling C$132.2 million (US$99.9 million).


“We have evolved significantly as an organization in the third quarter, solidifying our business growth strategy, and establishing our path forward from a clinical and regulatory development perspective,” said Roberto Bellini, President and Chief Executive Officer of BELLUS Health. “The past quarter was highlighted by our listing on the Nasdaq, and the completion of our US$79.4 million offering. We also bolstered our executive leadership with the appointment of industry veteran Dr. Cathy Bonuccelli to the position of Chief Medical Officer. Collectively, these achievements have positioned us for continued success, as we look toward the upcoming clinical and regulatory milestones for our product candidate, BLU-5937, in 2020.”


BLU-5937 for Chronic Cough


BELLUS Health is developing BLU-5937, a potent, highly selective, small molecule inhibitor of the P2X3 receptor, as an oral therapy to reduce cough frequency in refractory chronic cough patients.


BELLUS Health is currently conducting a Phase 2 clinical trial of BLU-5937 for patients with refractory chronic cough, which is referred to as the RELIEF (A Randomized, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Trial of BLU-5937 in Subjects with Unexplained or Refractory Chronic Cough) trial. The trial was initiated in July 2019 and the Company expects to report topline data in mid-2020.


The RELIEF trial is a randomized, double-blind, placebo-controlled, dose escalation and two-period crossover design trial to assess the efficacy, safety and tolerability of BLU-5937 at four doses: 25, 50, 100 and 200 mg BID. Doses are escalated at four-day intervals. Approximately 65 patients with refractory chronic cough are expected to be enrolled at approximately 15 clinical sites located in the United Kingdom and United States. BELLUS Health enrolled the first patient in the RELIEF trial at the end of July 2019 and is actively recruiting patients.


Phase 1 results showed that no subjects in the BLU-5937 arm receiving anticipated therapeutic doses reported any loss of taste perception, and only one subject out of 24 (<5%) reported transient and sporadic taste alteration only on the first day of dosing. No subject reported total loss of taste at any dose. The RELIEF trial will also collect taste adverse event data to potentially build on this clinical evidence.


Further details on BELLUS Health’s Phase 2 RELIEF trial for BLU-5937 can be found at https://clinicaltrials.gov/ct2/show/NCT03979638.


Currently, there is no therapy approved specifically for the treatment of refractory chronic cough, and the most advanced therapy in development has substantial tolerability issues, including significant taste alteration or loss. BLU-5937 may be a differentiated option, with little to no effect on taste.


BLU-5937 for Chronic Pruritus


In July 2019, BELLUS Health announced that it is developing BLU-5937 for a second indication, chronic pruritus. The Company believes BLU-5937 may be a viable treatment option for patients with chronic pruritus associated with atopic dermatitis (“AD”).


Preclinical studies conducted by BELLUS Health provided evidence that the ATP-induced hypersensitization mediated by P2X3 receptors in cutaneous C-fibers plays a key role in pruritus. In multiple animal models of pruritus, the Company observed that treatment with BLU-5937 resulted in significant anti-pruritic effect. The Company presented preclinical data on BLU-5937 in pruritus at the European Society for Dermatological Research Conference in September 2019.


BELLUS Health plans to initiate a randomized, double-blind, placebo-controlled, parallel group design Phase 2 clinical trial to assess the efficacy, safety, and tolerability of BLU-5937 in approximately 100 patients suffering from moderate to severe chronic pruritus associated with mild to moderate AD. The trial is expected to be a two-arm study comparing BLU-5937 to placebo, each administered orally, twice-daily (BID), for four weeks. The Company expects to initiate the trial in Q2 2020 and report topline data in mid-2021.


Read more here: https://www.quotemedia.com/portal/quote?qm_symbol=BLU&qmodStoryID=6892256027749964 

!
Thumb 8020 monitor 200200 2

8020 Admin

3 months ago

8020 Admin posted a press release BELLUS Health to Present at Jefferies Global Healthcare Conference in London in BELLUS HEALTH INC.

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company on Wednesday, November 20, 2019 at the Jefferies Global Healthcare Conference in London.


Presentation Details:


Event: Jefferies Global Healthcare Conference in London
Date/Time: Wednesday, November 20, 2019 at 9:20 a.m. GMT
Location: London


A live webcast may be accessed on the Events and Presentations page under the Investors & News section of BELLUS Health's website at www.bellushealth.com. Following the event, an archived webcast and presentation will be available on the Company’s website.


About BELLUS Health


BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.




Investors:
François Desjardins
Vice President, Finance
450-680-4525
fdesjardins@bellushealth.com

Solebury Trout
Chad Rubin
646-378-2947
crubin@troutgroup.com

Media:
Solebury Trout
Joshua R. Mansbach
646-378-2964
jmansbach@troutgroup.com


!
Thumb no photo

luc@mi3.ca

11 months ago

!